High Potency APIs Market to Grow at 8.7% CAGR to 2023

ReportsnReports offers a global report on “High Potency APIs /HPAPI Market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 216 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Get Sample Copy of High Potency APIs Market at https://www.reportsnreports.com/contacts/requestsample.aspx?name=828055

The Global HPAPIs Market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%.

Top Companies Profiled n the High Potency APIs Market:

  • Pfizer (US)
  • Novartis International AG (Switzerland)
  • Sanofi (France)
  • Hoffmann-La Roche (Switzerland)
  • Bristol-Myers Squibb (US)
  • Boehringer Ingelheim (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (US)
  • Merck (US)
  • AbbVie (US)
  • Mylan (US)
  • Bayer (Germany)

Based on type, the HPAPIs market is segmented into innovative and generic APIs. The generic HPAPIs segment is expected to register the highest growth rate during the forecast period. The impending patent cliff, increasing healthcare costs, and government initiatives to encourage the adoption of generics are the major factors driving the growth of this market segment.

On the basis of type of manufacturer, the HPAPIs market is segmented into captive HPAPI and merchant HPAPI manufacturers. In 2018, the captive HPAPI manufacturers segment is expected to account for the largest share of the market.

Access full report with all information @ https://www.reportsnreports.com/purchase.aspx?name=828055

Share This Post